Filing Flows › CytomX Therapeutics (CTMX) › Q2 2026 › vs Q2 2025
CytomX Therapeutics (CTMX) Q2 2026 vs Q2 2025 (year over year)
CytomX Therapeutics's revenue fell $17.2M (-92%) from $18.7M in Q2 2025 to $1.4M in Q2 2026.
CytomX Therapeutics, Q2 2026: revenue $1.4M (-92% year over year), net loss $20.7M, operating cash flow −$18.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.4M | $18.7M | −$17.2M | -92% |
| Other income, net | $3.2M | $1.2M | $2.0M | +166% |
| Net loss | $20.7M | $154K | $20.5M | 134× |
| Costs & expenses | $25.3M | $20.0M | $5.3M | +26% |
| Operating costs | $25.2M | $19.9M | $5.3M | +26% |
| Income tax | $60K | $63K | −$3K | -5% |
| Research & development | $17.6M | $13.3M | $4.3M | +32% |
| General & admin | $7.6M | $6.6M | $979K | +15% |
| Operating cash sources | $20.7M | $154K | $20.5M | 134× |
| Share-based compensation | $2.6M | $1.4M | $1.1M | +80% |
| Working capital & other | $21K | −$17.0M | $17.1M | — |
| Cash used in operations | $18.1M | $15.8M | $2.3M | +15% |
| Net loss absorbed | $20.7M | $154K | $20.5M | 134× |
Questions
How much did CytomX Therapeutics's revenue grow year over year in Q2 2026?
CytomX Therapeutics's revenue fell $17.2M (-92%) from $18.7M in Q2 2025 to $1.4M in Q2 2026.